NCT03478319View on ClinicalTrials.gov

A Study of ACE-2494 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 15, 2018

Primary Completion Date

June 13, 2019

Study Completion Date

June 17, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

ACE-2494 or placebo

Recombination fusion protein

Trial Locations (1)

G1P0A2

Syneos Health, Québec

All Listed Sponsors
lead

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

INDUSTRY

NCT03478319 - A Study of ACE-2494 in Healthy Subjects | Biotech Hunter | Biotech Hunter